BTIG Reiterates Buy on Celgene Corporation (CELG) Despite Weak International Revlimid Sales
In a research report released Thursday, BTIG analyst Dane Leone reiterated a Buy rating on shares of Celgene Corporation (NASDAQ:CELG) with a price target of $138, after the healthcare giant reported fourth-quarter earnings report, with EPS coming in at $1.61 (non-GAAP) and $5.94 (non-GAAP) for 2016. Guidance was maintained for 2017, as was longer term guidance for 2020.
Leone noted, “Weak growth of Revlimid sales OUS during 4Q16 became a focal point for investors, despite guidance for mid- to high-teens growth for Revlimid during 2017 (global). Although the seasonality of Revlimid sales during 4Q16 was high relative to history, we would not let it distract us from significant clinical catalysts expected during 1H17, namely the Phase III topline results for Ozanimod. We reiterate our Buy rating and $138 PT as we are positive on a number of clinical developments for CELG during 2017.”
According to TipRanks, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Dane Leone has a yearly average return of 7.8% and a 63% success rate. Leone has a 3.9% average return when recommending CELG, and is ranked #535 out of 4378 analysts.
Out of the 28 analysts polled in the past 12 months, 24 rate Celgene stock a Buy, while 4 rate the stock a Hold. With a return potential of 24%, the stock’s consensus target price stands at $139.33.
More stocks covered by top performing analysts can be found here.